<DOC>
	<DOCNO>NCT00466856</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : This phase II trial study well internal radiation therapy work treat patient liver metastasis neuroendocrine tumor .</brief_summary>
	<brief_title>Internal Radiation Therapy Treating Patients With Liver Metastases From Neuroendocrine Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine tumor response selective internal radiation therapy yttrium Y 90 resin microspheres ( Sir-Spheres® ) patient progressive liver metastasis neuroendocrine tumor . Secondary - Determine toxicity treatment patient . - Determine symptomatic relief patient treat regimen . - Determine health-related quality life patient receive treatment . OUTLINE : Patients catheter place hepatic artery percutaneously groin undergo selective internal radiation therapy yttrium Y 90 resin microspheres ( Sir-Spheres® ) via catheter day 1 . Patients also receive octreotide acetate IV 1 hour prior , , 2 hour Sir-Spheres® injection . Patients may undergo treatment another lobe liver ( lobe treat separately ) 4 week later . Patients undergo functional performance , health-related quality life , symptom severity assessment prior initial treatment completion study treatment . After completion study treatment , patient follow periodically least 1 year . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm neuroendocrine tumor metastatic liver Welldifferentiated moderately welldifferentiated neuroendocrine tumor Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan Symptomatic disease , meet one follow criterion : Refractory carcinoid symptom , define Carcinoid Symptom Severity scale &gt; 2 despite use octreotide acetate ≥ 200 mcg subcutaneously three time daily ( 20 mg intramuscularly monthly ) ≥ 4 week Evidence radiographic progression either follow manifestation : Moderatesevere right upper quadrant pain unintentional weight loss &gt; 10 % Decline Karnofsky performance status &gt; 10 point At least 20 % increase sum long diameter target lesion liver within past 12 month No 75 % replacement normal liver neuroendocrine tumor No 20 % arteriovenous lung shunt technetium Tc 99m macroaggregated albumin nuclear scan No equivocal , nonmeasurable , nonevaluable liver metastasis PATIENT CHARACTERISTICS : Karnofsky performance status 50100 % Life expectancy ≥ 6 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Creatinine ≤ 1.5 mg/dL Bilirubin ≤ 2.0 mg/dL Albumin ≥ 3.0 g/dL Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 65,000/mm³ Hemoglobin &gt; 9.0 g/dL INR ≤ 1.4 No hepatic arterial anatomy would preclude administration study treatment liver No nonmalignant disease would preclude study participation No malignancy within past 5 year except cure basal cell carcinoma skin cure carcinoma situ uterine cervix PRIOR CONCURRENT THERAPY : Prior surgery , chemotherapy , locally ablative technique liver cancer allow No prior radiotherapy upper abdomen include liver treatment field No investigational drug agent/procedure ( i.e. , participation another clinical trial ) within past 4 week No specific anticancer treatment ( octreotide acetate ) 3 month completion study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>neoplastic syndrome</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>metastatic pheochromocytoma</keyword>
	<keyword>recurrent islet cell carcinoma</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>recurrent pheochromocytoma</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>insulinoma</keyword>
	<keyword>WDHA syndrome</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>somatostatinoma</keyword>
</DOC>